![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Pharma Blog Watch
Pharma Blog Watch
Waxman
and Adaptive Trials (DrugWonks)
In his entry, Robert Goldberg discusses
Rep. Henry Waxman's (D-Calif.) views on adaptive clinical trials. According to
Waxman, "'Permitting drug companies to take shortcuts in their clinical trials
poses real risks to Americans.'
'An antibiotic that is no better than a
placebo can't fight off an infection'," Goldberg writes.
"It's hard to know even where to begin. Non-inferiority trials are not shortcuts. And asserting that an antibiotic that is no better than a placebo equals non-inferiority trials is scientifically wrong," he continues.
"Supposedly, FDA reviewers have sent signals that a drug intended to keep people alive whose transplanted organs are being rejected and have six hours to live on average should undergo placebo-controlled trials to determine safety," he writes. "I would argue that Waxman's micromanagement if this FDA anecdote even has a glint of truth to it borders on compromising the canons of science and the integrity of the entire drug evaluation process."
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct